Novel insights into mesothelioma biology and implications for therapy.
MetadataShow full item record
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and cisplatin combination chemotherapy) approved in the past 13 years. However, the past 5 years have witnessed an exponential growth in our understanding of mesothelioma pathobiology, which is set to revolutionize therapeutic strategies. From a genomic standpoint, mesothelioma is characterized by a preponderance of tumour suppressor alterations, for which novel therapies are currently in development. Other promising antitumour agents include inhibitors against angiogenesis, mesothelin and immune checkpoints, which are at various phases of clinical trial testing.
Tumor Suppressor Proteins
Genes, Tumor Suppressor
Genes, Neurofibromatosis 2
Proto-Oncogene Proteins c-akt
TOR Serine-Threonine Kinases
Phosphoinositide-3 Kinase Inhibitors
Medicine Drug Development Unit (de Bono)
License start date
Nature reviews. Cancer, 2017, 17 (8), pp. 475 - 488